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Abstract 
Objective: This article analyses the influence of treatment duration on survival in patients with invasive carcinoma 
of the cervix treated by radical radiation therapy. Method; Three hundred and sixty patients with FIG0 stage IB-IIIB 
carcinoma of the cervix were treated in Lausanne (Switzerland) with external radiation and brachytherapy as first line 
therapy. Median therapy duration was 45 days. Patients were classified according to the duration of the therapies, 
taking 60 days (the 75th percentile) as an arbitrary cut-off. Results: The 5-year survival was 61% (SE. = 3%) for the 
therapy duration group of less than 60 days and 53% (SE. = 7%) for the group of more than 60 days. In terms of 
univariate hazard ratio (HR), the relative difference between the hvo groups corresponds to a 50% increase of deaths 
(HR = 1.53, 95% CI = 1.03-2.28) for the longer therapy duration group (P = 0.044). In a multivariate analysis, the 
magnitude of estimated relative hazards for the longer therapies are confirmed though significance was reduced 
(HR = 1.52, 95% CI = 0.94-2.45, P = 0.084). Conclusion: These findings suggest hat short treatment duration is a 
factor associated with longer survival in carcinoma of the cervix. 0 1997 International Federation of Gynecology 
and Obstetrics 
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1. Introduction [l-3]. External irradiation and brachytherapy are 
combined in order to increase local control and 
Carcinoma of the uterine cervix can be effec- hence survival. Both treatment modalities may be 
tively treated with definitive radiation therapy applied. One of the unanswered questions is how 
to combine these two radiotherapeutic modalities. 
Should they be given sequentially or concomi- 
*Corresponding author. Tel.: +41 21 3143269; fax: + 41 21 tantly? Overall treatment time will depend upon 
3143263. the choice of the treatment sequence. 
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Recently the importance of overall treatment 
time has been highlighted in large series of 
patients treated by radiation therapy for cervical 
cancer [4-71. The importance of this particular 
prognostic factor for the outcome is supported by 
in vivo evidence of a short potential doubling 
time CT,,,) in cervical cancer [8]. This Tpot value, 
measured prior to treatment, is probably closely 
related to the kinetics of proliferative clonogenic 
cells during treatment, which is generally thought 
to be at the origin of failure to control the disease 
locally. To check the intrinsic importance of the 
sequencing of both treatment modalities and 
hence treatment duration, we decided to retro- 
spectively analyze a consecutive series of patients, 
treated by external radiation and brachytherapy. 
2. Methods 
2.1. Patients population 
From January 1971 to December 1992, 612 
consecutive patients with primary FIG0 stage 
IB-IIIB carcinoma of the cervix were treated with 
radiation therapy. Only 360 of them received both 
external radiation and brachytherapy, and were 
considered for the current study. Of the 252 
patients excluded, 114 received either external 
radiation or brachytherapy alone, 40 had been 
diagnosed too recently or had incomplete base- 
line data, and 98 had undergone total hysterec- 
tomy. Patients characteristics are summarized in 
Table 1. The median age was 60 years (range 
20-90 years). Baseline evaluation included physi- 
cal and pelvic examination, cervical biopsies, com- 
plete blood count, chemistry profile, chest X-ray, 
intravenous pyelogram or computerized tomogra- 
phy, cystoscopy and rectoscopy. Treatment vari- 
ables are described below and summarized in 
Table 2. 
2.2. Radiation therapy 
External radiation therapy was delivered ini- 
tially with a betatron (45 MeV) and later with a 
linear accelerator (6-18 MeV). The pelvic volume 
was approached using a four-field box technique. 
The dose per fraction generally was 180-200 








































IB-IIA received 45 Gy to the whole pelvis. Patients 
with advanced stage IIB-IIIB received 45 Gy to 
the pelvic volume and a lo-15 Gy boost to the 
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apy delivered a boost of 30 Gy to point A in l-3 
fractions for LDR and in 3 or 4 fractions over 3 
or 4 weeks for HDR. In the first decade 
(1971-1979), low dose-rate brachytherapy (LDR: 
90 cGy/h at point A) was systematically used, 
whereas from the second decade on, all patients 
were submitted to high dose-rate (HDR: 30 
cGy/min at point A). The isotope used for LDR 
was radium, and the isotope used for HDR was 
cesium. The rectal dose was measured during the 
insertion of the source and the total rectal dose 
for the whole period of brachytherapy was com- 
puted. External radiation therapy and intracavi- 
tary brachytherapy were performed concomitantly 
(Con) or sequentially (Seq). Sequential curiether- 
apy was given at weekly intervals, 5-20 days fol- 
lowing completion of external radiation. From 
1990 to 1993 radiation therapy was Seq in 92% of 
the patients. 
2.3. Total effect 
In 1980, when HDR curietherapy was intro- 
duced, the original Nominal Standard Dose (NSD) 
from Ellis and the modification proposed by Or- 
ton were used to calculate the biological equiva- 
lence of HDR vs. LDR [9,10]. For the present 
analysis the treatment related factors (total dose, 
number of fractions) were introduced in the lin- 
ear quadratic model modified according to the 
proposal of Fowler in order to calculate the Total 
Effect (TE) [ll]. For the curietherapy a correc- 
tion for the TE was introduced with the continu- 
ous repair model from Thames [12]. No correc- 
tions were made for overall treatment duration 
because no individual data are available either on 
pre-treatment potential doubling time, or on time 
of kick-off repopulation as suggested by Withers 
[13,14]. To facilitate the discussion, all doses will 
be expressed as TE in Gray squared (Gy2> for 
both external and brachytherapy treatments (see 
addendum). One should be aware that this TE is 
different from the real dose given at point A. It is 
a measure of the radiobiological effectiveness of 
the treatment for tumor tissue. For these calcula- 
tions some assumptions have been made concern- 
ing repair half-time (T1,2) and related continuous 
repair factor (g-factor). A T,,, of 1.5 h has been 
considered and the corresponding g-factor has 
been extrapolated according to the exposure time 
for both HDR and LDR. Moreover, the choice of 
the a/P factor, required for calculation of TE, 
does not really influence the results because the 
same value has been chosen for HDR as for 
LDR. This factor is merely a measure of the 
intrinsic sensitivity of the tumor tissue to a change 
in fraction size and is unrelated to the dose-rate. 
Total effect could not be calculated for 14 patients 
due to incomplete information on radiotherapy 
doses administered. Median total effect was 1283 
Gy”. For the purpose of this analysis patients 
were classified according to whether they had 
received treatment with rather low total effect? 
taking 1164 Gy* (the 25th percentile) as an ar- 
bitrary cut-off. 
2.4. Therapy duration 
This included the duration of external radiation 
therapy, the time interval between the former and 
brachytherapy, and the duration of brachyther- 
apy. Therapy duration was calculated in days. 
Median therapy duration was 45 days. For the 
purpose of the analysis, patients were classified 
according to whether they had rather long thera- 
pies, taking 60 days (the 75th percentile) as an 
arbitrary cut-off. 
2.5. Statistical methods 
The primary endpoint of this study was overall 
survival (OS), which was defined as time from 
beginning of radiation therapy to death. For the 
purpose of this analysis, survival status for all 
patients was updated during the summer of 1993. 
Statistical analyses were carried out by means 
of the software package Stata [151. Survival per- 
centages over time have been calculated by the 
Kaplan-Meier method [161 and their correspond- 
ing standard errors (S.E.) with Greenwood’s for- 
mula [17]. For univariate analysis of OS the P-val- 
ues from the log-rank test are reported for each 
comparison considered [181. Estimated hazard ra- 
tios (HR) of death, with respect to the indicated 
reference group, their 95% confidence intervals 
(95% CD and P-values were calculated with pro- 
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portional-hazard regression with appropriate bi- 
nary variables to identity each group of interest 
[19]. For the multivariate analysis, some cate- 
gories of variables have been collapsed to allow 
for small numbers of deaths in the respective 
subgroups. Values of HR greater than unity indi- 
cate increased rates of death with respect to the 
chosen reference category. For analyses other 
than on OS, chi-squared tests (for categorical 
variables) or Kruskall-Wallis tests (for continu- 
ous variables) have been used [20]. All probability 
values are for two-sided tests. For the purpose of 
the analyses of survival and unless otherwise indi- 
cated, observations have been censored at 5 years 
in order to limit the effect of competing causes of 
mortality and also to avoid having only patients 
registered during the earlier periods contribute to 
the right tail of the survival curves. Five-year 
survival is also considered a relevant endpoint for 
cervical cancer patients. 
3. Results 
3.1. Total effect and therapy duration 
Among patients treated with the sequential 
modality, median total effect was 1183 Gy2 as 
opposed to 1283 Gy2 in the group treated with 
the concomitant modality (P < 0.001). Similarly, 
as concerns therapy duration, the sequential and 
concomitant groups had a median duration of 72 
and 44 days, respectively (P < 0.001). 
The association among type of therapy on the 
one hand and total effect and duration on the 
other was also visible in terms of the percentage 
of patients in each therapy group with a total 
effect less than 1164 Gy2 (namely 38% for Seq 
and 21% for Con, P = 0.004) or with a therapy 
duration longer than 60 days (namely, 74% for 
Seq and 13% for Con, P < 0.001). In addition, of 
the therapies of more than 60 days, 32% had a 
total effect of less than 1164 Gy2, as opposed to 
22% of the therapies of less than 60 days (P = 
0.064). 
FIG0 stage I was more frequently treated with 
shorter therapies (P < 0.038) and with lower total 
effect (P < 0.001). No other associations between 
therapy descriptors and other clinical characteris- 
tics were identified. 
3.2. Survival analysis 
Median follow-up for the studied patients was 
in excess of 12 years. Median survival for the 
whole group was 7.5 years and the 5-year survival 
was 59% (S.E. = 3%). Fig. 1 displays the survival 
experience of the whole group. For the following 
analyses, survival has been censored at 5 years, as 
explained in the Statistical Considerations. When 
considering sub-groups, the 5-year survival for the 
Con and Seq groups was 60% (S.E. = 3%) and 
58% (S.E. = 8%), respectively (P = 0.226). Simi- 
larly, for the total effect groups less than 1164 
Gy2 and more than 1164 Gy2, the 5-year survival 
was 47% (SE. = 6%) and 63% (SE. = 3%), re- 
spectively (P = O.OlO), while for the therapy dura- 
tion groups of less than 60 days and more than 60 
days we observed a 5-year survival of 61% (S.E. = 
3%) and 53% (S.E. = 7%), respectively (P = 
0.044). In terms of univariate hazard ratio (HR), 
the relative difference between the two therapy 
duration groups corresponds to an increase in 
hazard of death of about 50% (HR = 1.53, 95% 
CI = 1.03-2.28) for the more than 60 days group 
with respect to the less than 60 days group. These 
and additional univariate results are displayed in 
Table 3. Figs. 2-4 display the survival experience 
of the sample, according to type, duration and 
total effect of therapy. 
In light of the associations observed among the 
various descriptors considered, which may also 
have an important effect on survival, a multivari- 
ate analysis has been performed to establish the 
residual effect of each of the variables studied 
after simultaneous adjustment of all other factors 
considered. The results are displayed in Table 4 
and confirm the association in magnitude of 
longer therapies with increased risk of death. The 
estimated relative hazard for longer therapies is 
as in the univariate analysis (HR = 1.52, 95% 
CI = 0.94-2.45) but with only borderline signifi- 
cance (P = 0.084). The indication of the univari- 
ate analysis concerning a possible role of total 
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Table 3 
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effect of therapy is not confirmed. Stage is still a 
strong predictor of survival. An exploratory analy- 
sis has been performed considering the whole of 
the follow-up available on each patient (no cen- 
soring at 5 years). A multivariate regression con- 
firms the effect of longer therapies (HR = 1.52, 
95% CI = 1.03-2.26, P = 0.037). 
4. Discussion 
The main issue of this study was to determine 
whether overall treatment time was an authentic 
prognostic factor, as it was already reported [4-61. 


































scription we have studied the role of this factor 
together with that of total dose (expressed in total 
effect) and type of therapy (concomitant and se- 
quential) which may be acting as confounders of 
the association of interest. Strong associations 
among treatment descriptors were observed. 
The univariate analysis showed that overall 
treatment time and total effect are of prognostic 
significance. The multivariate analysis confirmed 
the prognostic importance of overall treatment 
time and FIG0 stage, but not the role of total 
effect. The relative risk of death increased sig- 
nificantly when overall treatment time exceeded 
60 days. The possible influence of overall treat- 
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Fig. 1. Overall survival in all patients. 
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Fig. 4. Overall survival according to total effect: > 1164 Gy2 or I 1164 Gy*. 
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Table 4 



















I 1164 Gy* 
> 1164 Gy’ 
Therapy duration 
I 60 days 
> 60 days 


























ment time on outcome after radiation therapy has 
been extensively studied in head and neck cancer 
[ll]. Any prolongation of radiation treatment is 
potentially deleterious for local control and sur- 
vival. Fowler calculated a median rate of loss of 
local control of 14% (range 3-25%) per week of 
extra overall time [ll]. In cervical cancer, Girin- 
sky et al. [6] reported a loss of local control of 
approximately 1% per day, when treatment time 
exceeded 52-62 days. Lanciano et al. E51 showed 
that total treatment time duration was predictive 
for both local control and survival especially for 
FIG0 stage III. Fyles [4] also showed a highly 
significant association between pelvic control and 
treatment duration. The hypothesis of a rapid 
proliferation of clonogenic cells during the course 
of radiation therapy was highlighted by Withers 
[13,14]. We hypothesized that potential doubling 
time (T,,,) was shorter in cervical cancer than in 
head and neck cancer, pointing to rapid prolifer- 
ating tissue potentially escaping the treatment 
when gaps or unnecessary delays are introduced. 
The multivariate analysis in our series confirmed 
therapy duration as a significant prognostic fac- 
tor. 
Several sources of bias may have affected the 
results of this retrospective analysis. Chronologic 
time (more than 20 years have elapsed since the 
first patient was registered), patient selection, di- 
agnostic accuracy, tailoring of total dose accord- 
ing to stage and response during treatment, or 
data quality might have acted as confounders. 
There are no obvious reasons to suggest that 
these factors would not have similarly affected all 
subgroups. However, other considerations may 
also contribute to the strength of the observed 
results. In particular, our patients have been 
treated by a single institution, where traditionally, 
treatment choices have been dictated primarily by 
the therapeutic philosophies of successive teams 
of clinical staff. Despite this, we have considered 
in the multivariate analysis, most of the prognos- 
tic factors which may also have affected treat- 
ment choice. In addition, we have simultaneously 
been able to address the issues of treatment 
duration and total effect in patients treated with 
either the concomitant or sequential modalities 
and allowing for the effect of surgery, thus ac- 
counting for most of the variation in survival 
attributable to treatment. Our study does not 
allow us to conclude that treatment time must be 
less than 60 days, since this threshold was ar- 
bitrarily chosen as a cut-off. Based on our results, 
we decided to apply brachytherapy (30 Gy to 
point A) concomitantly with the external irradia- 
tion (45 Gy to the pelvic volume and a boost of 
lo-15 Gy to the involved parameters). In order to 
optimize the geographical distribution of the dose 
within the tumor, this brachytherapy is applied at 
the end of the external treatment. This therapy 
schedule therefore reduces overall duration to 
less than 60 days. 
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5. Addendum 
Calculation of total effect (TE) expressed in Gy * 
For HDR or LDR treatment 
TE, =((~/P+dxg)nxd 
d = dose per application 
n = number of applications 
g = continuous repair factor 
a/P = 10 Gy 
g-values, assuming a repair half-time of 1.5 h 
(obtained by extrapolation from tabulated 
values) [ 121 
g uDR = 0.88 (application duration rt 20 min) 
g,,, = 0.16 (application duration * 24 h) 
For external radiation therapy 
TE,=(cw/P+d)n xd 
d = dose per fraction 
y1= number of fractions 
a/P = 10 Gy 
Cumulative total effect (TE, > 
TE,. = TE, + TE, 
Examples: 
1. HDR (4 x 10 Gy) 
TE, = (10 Gy + 10 Gy x 0.88)4 x 10 Gy 
= 752 Gy” 
2. External radiation therapy (25 x 1.8 Gy 
= 45 Gy) 
TE, = (10 Gy + 1.8 Gy)25 X 1.8 Gy = 531 Gy2 
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